Patient characteristics that can predict response to omalizumab an (Anti-IgE Antibody) for achieving better control of asthmatic patients
Background: Omalizumab is a monoclonal anti-immunoglobulin E (IgE) antibody indicated for the treatment of inadequately controlled severe persistent asthma despite optimal controller therapy. It is an expensive medication so there is a need to identify those patients most likely to benefit. Aim of t...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2012-07-01
|
| Series: | Egyptian Journal of Chest Disease and Tuberculosis |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0422763812000167 |